These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19800752)

  • 1. CTX-M and ampC beta-lactamases contributing to increased prevalence of ceftriaxone-resistant Escherichia coli in Changi General Hospital, Singapore.
    Tan TY; Ng LS; He J; Hsu LY
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):210-3. PubMed ID: 19800752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of resistance to expanded-spectrum cephalosporins in Escherichia coli isolates recovered in a Spanish hospital.
    Briñas L; Lantero M; de Diego I; Alvarez M; Zarazaga M; Torres C
    J Antimicrob Chemother; 2005 Dec; 56(6):1107-10. PubMed ID: 16239288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sporadic occurrence of CMY-2-producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway.
    Naseer U; Haldorsen B; Simonsen GS; Sundsfjord A
    Clin Microbiol Infect; 2010 Feb; 16(2):171-8. PubMed ID: 19548922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence, prevalence and genetic environment of CTX-M beta-lactamases in Enterobacteriaceae from Indian hospitals.
    Ensor VM; Shahid M; Evans JT; Hawkey PM
    J Antimicrob Chemother; 2006 Dec; 58(6):1260-3. PubMed ID: 17071956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of broad-spectrum cephalosporin-resistant Escherichia coli isolates in food samples in Tunisia, and characterization of integrons and antimicrobial resistance mechanisms implicated.
    Ben Slama K; Jouini A; Ben Sallem R; Somalo S; Sáenz Y; Estepa V; Boudabous A; Torres C
    Int J Food Microbiol; 2010 Feb; 137(2-3):281-6. PubMed ID: 20031243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTX-M-producing Escherichia coli in a maternity ward: a likely community importation and evidence of mother-to-neonate transmission.
    Dubois V; De Barbeyrac B; Rogues AM; Arpin C; Coulange L; Andre C; M'zali F; Megraud F; Quentin C
    J Antimicrob Chemother; 2010 Jul; 65(7):1368-71. PubMed ID: 20466850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular epidemiology of Escherichia coli producing extended-spectrum {beta}-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15.
    Blanco M; Alonso MP; Nicolas-Chanoine MH; Dahbi G; Mora A; Blanco JE; López C; Cortés P; Llagostera M; Leflon-Guibout V; Puentes B; Mamani R; Herrera A; Coira MA; García-Garrote F; Pita JM; Blanco J
    J Antimicrob Chemother; 2009 Jun; 63(6):1135-41. PubMed ID: 19351692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.
    Oteo J; Orden B; Bautista V; Cuevas O; Arroyo M; Martínez-Ruiz R; Pérez-Vázquez M; Alcaraz M; García-Cobos S; Campos J
    J Antimicrob Chemother; 2009 Oct; 64(4):712-7. PubMed ID: 19671590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15.
    Yumuk Z; Afacan G; Nicolas-Chanoine MH; Sotto A; Lavigne JP
    J Antimicrob Chemother; 2008 Aug; 62(2):284-8. PubMed ID: 18453527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in the prevalence of extended-spectrum-beta-lactamase-producing Escherichia coli in Japan by clonal spread.
    Suzuki S; Shibata N; Yamane K; Wachino J; Ito K; Arakawa Y
    J Antimicrob Chemother; 2009 Jan; 63(1):72-9. PubMed ID: 19004839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study.
    Simner PJ; Zhanel GG; Pitout J; Tailor F; McCracken M; Mulvey MR; Lagacé-Wiens PR; Adam HJ; Hoban DJ;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):326-34. PubMed ID: 21353961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and types of extended-spectrum beta-lactamases among urinary Escherichia coli and Klebsiella spp. in New Zealand.
    Heffernan HM; Woodhouse RE; Pope CE; Blackmore TK
    Int J Antimicrob Agents; 2009 Dec; 34(6):544-9. PubMed ID: 19748232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTX-M and SHV-12 beta-lactamases are the most common extended-spectrum enzymes in clinical isolates of Escherichia coli and Klebsiella pneumoniae collected from 3 university hospitals within Korea.
    Kim J; Lim YM; Rheem I; Lee Y; Lee JC; Seol SY; Lee YC; Cho DT
    FEMS Microbiol Lett; 2005 Apr; 245(1):93-8. PubMed ID: 15796985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of Romanian fluoroquinolone-resistant human clinical Escherichia coli isolates.
    Usein CR; Tatu-Chiţoiu D; Nica M; Ciontea SA; Palade AM; Condei M; Damian M
    Roum Arch Microbiol Immunol; 2008; 67(1-2):23-9. PubMed ID: 19284163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology.
    Rodríguez-Baño J; López-Cerero L; Navarro MD; Díaz de Alba P; Pascual A
    J Antimicrob Chemother; 2008 Nov; 62(5):1142-9. PubMed ID: 18641033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominance of CTX-M-2 and CTX-M-56 among extended-spectrum beta-lactamases produced by Klebsiella pneumoniae and Escherichia coli isolated in hospitals in Paraguay.
    Khan MA; Lemmens N; Riera E; Blonk T; Goedhart J; Van Belkum A; Goessens W; Hays JP; Van Westreenen M
    J Antimicrob Chemother; 2009 Dec; 64(6):1330-2. PubMed ID: 19854861
    [No Abstract]   [Full Text] [Related]  

  • 17. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.
    Gudiol C; Calatayud L; Garcia-Vidal C; Lora-Tamayo J; Cisnal M; Duarte R; Arnan M; Marin M; Carratalà J; Gudiol F
    J Antimicrob Chemother; 2010 Feb; 65(2):333-41. PubMed ID: 19959544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France.
    Leflon-Guibout V; Blanco J; Amaqdouf K; Mora A; Guize L; Nicolas-Chanoine MH
    J Clin Microbiol; 2008 Dec; 46(12):3900-5. PubMed ID: 18842941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of resistance and mobility among multidrug-resistant CTX-M-producing Escherichia coli from Canadian intensive care units: the 1st report of QepA in North America.
    Baudry PJ; Nichol K; DeCorby M; Lagacé-Wiens P; Olivier E; Boyd D; Mulvey MR; Hoban DJ; Zhanel GG
    Diagn Microbiol Infect Dis; 2009 Mar; 63(3):319-26. PubMed ID: 19216943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTX-M-1-related extended-spectrum beta-lactamases producing Escherichia coli: so far a sporadic event in Western Austria.
    Prelog M; Fille M; Prodinger W; Grif K; Brunner A; Würzner R; Zimmerhackl LB
    Infection; 2008 Aug; 36(4):362-7. PubMed ID: 18574554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.